RET and medullary thyroid gland carcinoma: After treatment with selpercatinib, complete and durable response of the measurable brain and leptomeningeal metastases was demonstrated in a M918T RET-mutant MTC patient who experienced previous disease progression on cabozantinib and radiation therapy (140).